Mossman K - Search Results

1

Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1.

Hoang HD, Said A, Vaidya N, Gilchrist VH, Malone K, Kabilan U, Topshee S, Xiang X, Yang AD, Olagnier D, Mossman K, Beug ST, Jafarnejad SM, Workenhe ST, Graber TE, Alain T. Hoang HD, et al. Among authors: mossman k. J Immunother Cancer. 2023 Mar;11(3):e006408. doi: 10.1136/jitc-2022-006408. J Immunother Cancer. 2023. PMID: 36958764 Free PMC article.

2

Bovine herpesvirus type 1 as a novel oncolytic virus.

Rodrigues R, Cuddington B, Mossman K. Rodrigues R, et al. Among authors: mossman k. Cancer Gene Ther. 2010 May;17(5):344-55. doi: 10.1038/cgt.2009.77. Epub 2009 Nov 6. Cancer Gene Ther. 2010. PMID: 19893594

3

Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype.

Cuddington BP, Dyer AL, Workenhe ST, Mossman KL. Cuddington BP, et al. Among authors: mossman kl. Cancer Gene Ther. 2013 May;20(5):282-9. doi: 10.1038/cgt.2013.18. Epub 2013 Apr 26. Cancer Gene Ther. 2013. PMID: 23618948

4

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Workenhe ST, Mossman KL. Workenhe ST, et al. Mol Ther. 2014 Feb;22(2):251-256. doi: 10.1038/mt.2013.220. Epub 2013 Oct 19. Mol Ther. 2014. PMID: 24048442 Free PMC article. Review.

5

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Workenhe ST, et al. Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9. Mol Ther. 2014. PMID: 24343053 Free PMC article.

6

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.

Workenhe ST, Mossman KL. Workenhe ST, et al. Oncoimmunology. 2013 Dec 1;2(12):e27138. doi: 10.4161/onci.27138. Epub 2013 Dec 9. Oncoimmunology. 2013. PMID: 24498567 Free PMC article.

7

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Workenhe ST, et al. Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19. Cancer Immunol Res. 2013. PMID: 24777969

8

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

Workenhe ST, Verschoor ML, Mossman KL. Workenhe ST, et al. Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Future Oncol. 2015. PMID: 25686121 Review.

9

Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Workenhe ST, Ketela T, Moffat J, Cuddington BP, Mossman KL. Workenhe ST, et al. Among authors: mossman kl. Oncogene. 2016 May 12;35(19):2465-74. doi: 10.1038/onc.2015.303. Epub 2015 Aug 10. Oncogene. 2016. PMID: 26257065

10

S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3.

Wang F, Alain T, Szretter KJ, Stephenson K, Pol JG, Atherton MJ, Hoang HD, Fonseca BD, Zakaria C, Chen L, Rangwala Z, Hesch A, Chan ESY, Tuinman C, Suthar MS, Jiang Z, Ashkar AA, Thomas G, Kozma SC, Gale M Jr, Fitzgerald KA, Diamond MS, Mossman K, Sonenberg N, Wan Y, Lichty BD. Wang F, et al. Among authors: mossman k. Nat Immunol. 2016 May;17(5):514-522. doi: 10.1038/ni.3433. Epub 2016 Apr 4. Nat Immunol. 2016. PMID: 27043414 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

263 results

Search Page